Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Brusamolino, A."'
Autor:
Emanuela Bonoldi, Andrea Toniato, Joseph Scibilia, Marta Piantanida, Scarlett Valeria Bernal Ortiz, Michele Nichelatti, Eleonora Brusamolino, Chiara Gamba, Linda Borgonovo, Valentina S. Caputo, Jan Walter Schroeder, Elide A. Pastorello, Valeria Fabbri, Luca Giuseppe Balossi
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 7072, p 7072 (2021)
International Journal of Molecular Sciences
Volume 22
Issue 13
International Journal of Molecular Sciences
Volume 22
Issue 13
DRESS/DiHS is a complex and potentially fatal drug reaction. Little is known about risk factors and elements that can help to identify patients with a severe reaction early. The aim of the study was to investigate those factors favoring the disease a
Autor:
Claudio Agostinelli, Nicola Cascavilla, Monica Balzarotti, Ercole Brusamolino, Gianluca Gaidano, Alessia Castellino, Annalisa Chiappella, Giovannino Ciccone, Luigi Rigacci, Francesco Zaja, Caterina Stelitano, Andrea Evangelista, Alessandra Tucci, Angela Congiu, Eleonora Russo, Manuel Gotti, Stefano Pileri, Giuseppe Rossi, Maria Giuseppina Cabras, Maurizio Martelli, Angelo Michele Carella, Emanuele Angelucci, Vincenzo Pavone, Umberto Vitolo, Alfonso Maria D'Arco, Francesco Merli
Summary Background The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::751c9226cb6cc1953c4dd728d6d6503d
http://hdl.handle.net/11573/994819
http://hdl.handle.net/11573/994819
Autor:
Antonella Anastasia, Pier Luigi Zinzani, Francesco Zaja, Simonetta Viviani, Stefano Luminari, Cinzia Pellegrini, Lisa Argnani, Barbara Botto, Armando Santoro, Paolo Corradini, Umberto Vitolo, Michele Spina, Alessandro Massimo Gianni, Enrico Derenzini, Ercole Brusamolino
Clinical trial results indicate that brentuximab vedotin brings considerable promise for the treatment of patients with relapsed or refractory Hodgkin’s lymphoma. A retrospective multicenter study was conducted on 65 heavily pretreated patients who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3824c3f840b2ea02e72efdaabb01d7b7
https://hdl.handle.net/11368/2953688
https://hdl.handle.net/11368/2953688
Autor:
Renato Fanin, Stefano Volpetti, Elena Sabattini, Maurizio Bonfichi, Flavia Salvi, Chiara Monagheddu, Stefano De Luca, Alessandra Tucci, Alessandro Levis, Ercole Brusamolino, Francesco Zaja, Umberto Vitolo, Monica Balzarotti, Lorella Orsucci, Chiara Rusconi, Erika Ravelli, Angelo Vacca, Stefano Pileri, Chiara Bottelli, Roberto Ria
BACKGROUND: Preclinical studies have highlighted the activity of lenalidomide in mantle cell lymphoma and its anti-proliferative synergy with dexamethasone. DESIGN AND METHODS: In this prospective, multicenter, phase II study, patients with relapsed/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9148fab186508349cbb34cdcefd62591
http://hdl.handle.net/11390/881108
http://hdl.handle.net/11390/881108
Autor:
Angelo Michele Carella, Giorgia Annechini, Emanuele Angelucci, Antonella Anastasia, Marcello Rodari, Eleonora Russo, Laura Giordano, Manuel Gotti, Armando Santoro, Roberta Murru, Monica Balzarotti, Alessandro Re, Ercole Brusamolino, Caterina Stelitano, Massimo Magagnoli, Angelagiovanna Congiu, Vittorio Ruggero Zilioli, Maurizio Bonfichi, Rita Mazza, Michele Spina, Flavia Salvi, Umberto Vitolo, Stefania Massidda, Barbara Botto, Francesco Merli
Publikováno v:
Leukemialymphoma. 57(10)
This randomized, multicenter study evaluates the addition of bortezomib (13 mg/m(2)) to IGEV (B-IGEV) in patients with relapsed/refractory Hodgkin Lymphoma (HL). Patients received either four courses of IGEV alone (n = 40) or B-IGEV (n = 40). The pri
Publikováno v:
Clinical Investigation. 1:989-997
The introduction of rituximab in combination with chemotherapy has substantially changed the outcome of patients with diffuse large B-cell lymphoma. This update will discuss the factors that improved our predictive capacity in these lymphomas and the
Autor:
Simonetta Viviani, Laura Giordano, Patrizia Pregno, Stefan Hohaus, Ercole Brusamolino, Paolo Corradini, Alessandro Pulsoni, Antonella Anastasia, Flavia Salvi, Chiara Rusconi, Armando Santoro, Stefano Luminari, Carmelo Carlo-Stella
Publikováno v:
British Journal of Haematology. 166:140-142
Autor:
Ercole Brusamolino, Emanuela Boveri, Cristiana Pascutto, Elisa Rumi, Mario Lazzarino, Marzia Varettoni, Chiara Elena, Luca Arcaini, Cesare Astori, Daniela Pietra, Paolo Bernasconi, Sabrina Boggi, Francesco Passamonti
Publikováno v:
Haematologica. 93:1645-1651
Essential thrombocythemia is a chronic myeloproliferative disorder; patients with this disorder have a propensity to develop thrombosis, myelofibrosis, and leukemia.We studied 605 patients with essential thrombocythemia (follow-up 4596 person-years)
Autor:
Ercole Brusamolino
Publikováno v:
European Journal of Cancer Supplements. 6:31-36
The development of variations of the cyclophosphamide, vincristine, doxorubicin and prednisone (CHOP) chemotherapy standard regimen has led in recent years to significant improvements in the outcome of patients with lymphoma. Such regimens include th
Autor:
Ester Orlandi, Mario Lazzarino, Marco Paulli, Paolo Bernasconi, Silvia Zibellini, Ilaria Giardini, Anna Maria Tenore, Marina Boni, Ercole Brusamolino, Mara De Amici, Alessandra Algarotti, Laura Vanelli, Vittorio Perfetti
Publikováno v:
Annals of Hematology. 86:619-622
Dear Editor, B-cell chronic lymphocytic leukemia (B-CLL) patients with unmutated IgV genes frequently show trisomy 12 and a poor clinical outcome, while those with mutated IgV genes often show 13q14 deletions (13q−) and a favorable prognosis [1]. A